abstract tnfs are major mediators of inflammation and inflammation-related diseases, hence, the united states food and drug administration (fda) has approved the use of blockers of the cytokine, tnf-Î±, for the treatment of osteoarthritis, inflammatory bowel disease, psoriasis and ankylosis.